Recent submissions
Now showing items 21-40 of 889
-
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia.
(ELSEVIER SCIENCE INC, 2019-05-01)IKZF1 deletion (ΔIKZF1) is an important predictor of relapse in both childhood and adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Previously, we revealed that COBL is a hotspot for breakpoints in leukemia and ... -
Uridine-derived ribose fuels glucose-restricted pancreatic cancer.
(NATURE PORTFOLIO, 2023-06-01)Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to therapy1,2. This is mediated in part by a complex tumour microenvironment3, low vascularity4, and metabolic aberrations5,6. Although altered ... -
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma.
(NATURE PORTFOLIO, 2020-07-01)Remarkable progress in molecular analyses has improved our understanding of the evolution of cancer cells toward immune escape1-5. However, the spatial configurations of immune and stromal cells, which may shed light on ... -
DNA methylation-based classification of glioneuronal tumours synergises with histology and radiology to refine accurate molecular stratification.
(WILEY, 2023-04-01)AIMS: Glioneuronal tumours (GNTs) are poorly distinguished by their histology and lack robust diagnostic indicators. Previously, we showed that common GNTs comprise two molecularly distinct groups, correlating poorly with ... -
The biology and treatment of leiomyosarcomas.
(ELSEVIER SCIENCE INC, 2023-04-01)Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS. There is substantial interpatient heterogeneity ... -
RANK is a poor prognosis marker and a therapeutic target in ER-negative postmenopausal breast cancer.
(WILEY, 2023-04-11)Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed ... -
First passage time analysis of spatial mutation patterns reveals sub-clonal evolutionary dynamics in colorectal cancer.
(PUBLIC LIBRARY SCIENCE, 2023-03-01)The signature of early cancer dynamics on the spatial arrangement of tumour cells is poorly understood, and yet could encode information about how sub-clones grew within the expanding tumour. Novel methods of quantifying ... -
USP7 controls NGN3 stability and pancreatic endocrine lineage development.
(NATURE PORTFOLIO, 2023-04-28)Understanding the factors and mechanisms involved in beta-cell development will guide therapeutic efforts to generate fully functional beta cells for diabetes. Neurogenin 3 (NGN3) is the key transcription factor that marks ... -
Technical note on the exploration of COVID-19 in autopsy material.
(BMJ PUBLISHING GROUP, 2023-01-30)Interrogation of immune response in autopsy material from patients with SARS-CoV-2 is potentially significant. We aim to describe a validated protocol for the exploration of the molecular physiopathology of SARS-CoV-2 ... -
Molecular profiling in desmoplastic small round cell tumours.
(PERGAMON-ELSEVIER SCIENCE LTD, 2023-04-01)Desmoplastic small round cell tumour (DSRCT) is an ultra-rare soft tissue sarcoma that is characterised by aggressive disease and dismal patient outcomes. Despite multi-modal therapy, prognosis remains poor and there are ... -
Immune selection determines tumor antigenicity and influences response to checkpoint inhibitors.
(NATURE PORTFOLIO, 2023-03-01)In cancer, evolutionary forces select for clones that evade the immune system. Here we analyzed >10,000 primary tumors and 356 immune-checkpoint-treated metastases using immune dN/dS, the ratio of nonsynonymous to synonymous ... -
Recurrent FOSL1 rearrangements in desmoplastic fibroblastoma.
(WILEY, 2023-02-01)The FOS gene family has been implicated in tumourigenesis across several tumour types, particularly mesenchymal tumours. The rare fibrous tumour desmoplastic fibroblastoma is characterised by overexpression of FOSL1. ... -
The Interplay of Cesarean-Section Delivery and First-Birth Order as Risk Factors in Acute Lymphoblastic Leukemia.
(AMER ASSOC CANCER RESEARCH, 2023-03-06)BACKGROUND: Childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL) has been associated with early-life exposures, including birth by cesarean section (C-section), and a deficit of social exposure (first child). ... -
Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia.
(SPRINGERNATURE, 2023-01-01) -
Spatial interrogation of tumour microenvironment using artificial intelligence
(Institute of Cancer Research (University Of London), 2023-03-06)The tumour microenvironment can provide critical information for disease diagnosis, treatment planning, and prognosis. However, the complexity of its morphological, cellular, and spatial architecture hinders accurate ... -
Proteomics uncover EPHA2 as a potential novel therapeutic target in colorectal cancer cell lines with acquired cetuximab resistance.
(SPRINGER, 2022-11-19)BACKGROUND: In metastatic colorectal cancer (mCRC), acquired resistance against anti-EGFR targeted monoclonal antibodies, such as cetuximab (CET), was shown to be frequently caused by activating alterations in the RAS genes ... -
Improving the multiple myeloma patient pathway: microsampling for remote monitoring of free light chains
(Institute of Cancer Research (University Of London), 2023-01-24)Multiple myeloma (MM) is categorised as a relapsing-remitting blood cancer with unpredictable relapse patterns. Due to an inevitable relapse, blood test monitoring is crucial and requires frequent visits to the phlebotomy ... -
The comprehensive proteomic characterisation of soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-01-04)Soft tissue sarcomas (STS) are a group of rare and heterogeneous mesenchymal malignancies. The extensive clinical and biological heterogeneity of STS complicates clinical disease management, and in the advanced setting ... -
Molecular subtypes of leiomyosarcoma: Moving toward a consensus
(WILEY, 2022-12-01) -
Advances in immunotherapy for MMR proficient colorectal cancer.
(ELSEVIER SCI LTD, 2022-12-01)Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect ...